On behalf of Genentech, I have enclosed data for the NCCN Ovarian Cancer Guideline Panel on Tarceva® (erlotinib) as maintenance treatment for patients with ovarian, primary peritoneal, or fallopian tube cancer.

**Specific Changes:** For your information, data on the use of Tarceva® (erlotinib) as maintenance treatment after first-line chemotherapy for patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer was recently presented.1,2

**FDA Clearance:** The FDA has not approved Tarceva for the maintenance treatment of ovarian cancer. Please refer to the enclosed prescribing information for the full FDA-approved indications and safety information.3

**Rationale:** A Phase III, randomized, multicenter, international study evaluated Tarceva versus observation in patients with high-risk Stage I or Stage II-IV (FIGO stage) ovarian, tubal, or peritoneal cancer who did not progress after 6-9 courses of platinum-based chemotherapy.1,2 This study was sponsored by the Gynecologic Cancer InterGroup (GCIG) and European Organisation for Research and Treatment of Cancer (EORTC)-Gynaecological Cancer Group (GCG). The primary endpoint, progression-free survival, was not statistically significant between treatment groups.

Additional data on the use of Tarceva for the treatment of ovarian cancer have previously been reported.4-15

Due to copyright restrictions, we are unable to provide a reprint of the abstract or presentation at this time. Please see www.asco.org to view the abstract.

Respectfully submitted,

Encl: Tarceva prescribing information

cc: Iris Tam, PharmD, Director, Genentech Medical Communications
Cited References


3. Tarceva Prescribing Information


© Genentech, Inc. All rights reserved.
